

Table of Contents

Guest Editor for this issue:
Ivan Robbins, MD

4 Profiles in Pulmonary Hypertension:
Jim Loyd, MD

5 BMPR2 Mutations:
Role and Clinical Relevance

15 TGF-beta Receptors in PAH: HHT Connection

20 The Serotonin Pathway in PH

24 Genetic Contributions to Nonidiopathic, Nonfamilial PH

30 The Future of Genetics in PH

Publisher

Pulmonary Hypertension Association
Jack Stibbs, *Chair of the Board*
Rino Aldrighetti, *President*
Justine Elliot, *Medical Services Manager*

Publishing Staff

Stu Chapman, *Executive Editor*
Susan Chapman, *Managing Editor*
Heidi Green, *Associate Editor*
Gloria Catalano, *Production Director*
Michael McClain, *Design Director*

PHA Office

Pulmonary Hypertension Association
850 Sligo Avenue, Suite 800
Silver Spring, MD 20910
301-565-3004, 301-565-3994 (fax)
www.phassociation.org

Provided through an unrestricted educational grant
from Actelion Pharmaceuticals, U.S., Inc. and
Accredo Therapeutics.

© 2004 by Pulmonary Hypertension Association and Data Medica.
All rights reserved. None of the contents may be reproduced in
any form whatsoever without the written permission of PHA.

Editorial Offices

Advances in Pulmonary Hypertension, DataMedica,
P.O. Box 1688, Westhampton Beach, NY 11978
Tel (631) 288-7733 Fax (631) 288-7744
E-mail: Sue@immunotherapy.org

Advances in Pulmonary Hypertension is circulated to cardiologists, pulmonologists, rheumatologists and other selected physicians by the Pulmonary Hypertension Association. The contents are independently determined by the Editor and the Editorial Advisory Board.

Cover image: A sequence of nucleotides in a strand of DNA as depicted in an illustration by Doug Struthers, Copyright, 2005.

Printed on recycled paper.

Editor's Memo

Passing the Torch: New Editorial Team Offers Broadest Spectrum of Expert Medical Opinion in Pulmonary Hypertension



This issue of *Advances in Pulmonary Hypertension* renews our commitment to the pulmonary hypertension community to provide valuable, timely, peer-reviewed scientific information relevant to clinical practice. Beginning with its first issue more than 3 years ago, the journal has embodied a team effort. Reflecting the fact that pulmonary hypertension is a complex disease, our editorial focus has been derived from experts whose areas of concentration reflect the diverse nature of this disorder and its complications.

As I assume the role of Editor-in-Chief, I pursue the same strategy because it has served us well. We will continue to build on a team effort of national and international experts whose goal is to find a cure for pulmonary hypertension. While the cure remains elusive, we are finding significant ways to improve the quality of life of patients with the disease; the journal serves as a chronicle of that story as it focuses on important developments in translational research and relates them to clinical considerations and decisions.

We are challenged by and appreciative of the leadership provided during the first 3 years of publication. We gratefully acknowledge the hard work and guidance provided by Victor F. Tapson, MD, Editor-in-Chief during this time. His contribution to the launch of the journal has left us with a solid foundation on which to build. His high editorial standards give us a legacy to live up to and the enthusiastic response to the journal from 30,000 readers makes us proud of Vic's contribution. We are also grateful for the guidance provided by the Editorial Advisory Board of Richard N. Channick, MD, Sean Gaine, MD, PhD, Ronald J. Oudiz, MD, and Ivan M. Robbins, MD. The help from these leading academicians in identifying appropriate topics, participating in roundtable discussions and ensuring the overall quality of content inspires us to continue their excellent work.

With this issue, you will see more evidence of our team approach to pulmonary hypertension. Drs Channick and Oudiz will remain as Associate Editors, and we have added Ramona Doyle, MD, Karen Fagan, MD, and Oliver Sitbon, MD. Our Editorial Advisory Board has been expanded because more physicians have expressed a special interest in the journal and we look forward to working with them throughout the year as they participate in the editorial process. These physicians include: Gregory Ahearn, MD, Jacques Benisty, MD, Raymond Benza, MD, Erika Berman-Rosenzweig, MD, Todd Bull, MD, Murali Chakinala, MD, Jeffrey Edelman, MD, Jim Maloney, MD, Robert Schiltz, DO, and Roxana Sulica, MD.

The result will be a journal that reflects the broadest possible spectrum of expert medical opinion in pulmonary hypertension. The journal also benefits from the expertise of the Scientific Leadership Council of the Pulmonary Hypertension Association (PHA). As the official journal of PHA, *Advances in Pulmonary Hypertension* will continue to be in the forefront of patient advocacy and awareness concerning the availability of new research grants as well, serving as the most comprehensive resource for such information.

The enthusiastic response from our readers is another key factor in renewing our commitment to the pulmonary hypertension community. We look forward to hearing from you regarding the usefulness of the content and welcome your suggestions and comments as we work toward providing you with a journal you look forward to reading, saving, and sharing with colleagues.

Vallerie V. McLaughlin, MD
Editor-in-Chief